Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene regulatory network analysis identifies auranofin as an anti-atherosclerotic drug

ABSTRACT: This SuperSeries is composed of the SubSeries listed below. Gene-regulatory networks (GRNs) offer a mechanistic framework for dissecting the complex molecular and genetic architecture of coronary artery disease and for identifying new therapeutic opportunities. Here, we present a GRN-driven drug-repurposing strategy that integrates transcriptional signatures induced by silencing key drivers of the human arterial wall foam cell regulator GRN 42 with drug-induced gene expression profiles from the NIH LINCS program. In vitro screening of top candidate compounds validates the computational predictions, identifying candidate foam cell modulators and showing that auranofin, an FDA-approved gold salt used to treat rheumatoid arthritis, effectively reduces foam cell formation. In vivo, auranofin attenuates atherosclerosis and inflammation in both male mice and rabbits. Clinically, auranofin was associated with reduced cardiovascular risk in a retrospective cohort of patients with rheumatoid arthritis. Together, these findings show that a GRN-based drug-repurposing framework, coupled with preclinical and clinical validation, can uncover new therapeutic applications for existing drugs, including auranofin, in coronary artery disease.

ORGANISM(S): Mus musculus Homo sapiens

PROVIDER: GSE293699 | GEO | 2026/04/01

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Gene Regulatory Network-Driven Drug Repurposing Identifies Anti-Atherosclerotic Properties of Auranofin [dataset 2]

Project description:The identification of new therapies for coronary artery disease (CAD) has been challenging due to its inherent molecular complexity, which involves thousands of genes acting within and across tissues and cells. Gene-regulatory networks (GRNs) address this complexity by providing a mechanistic framework for common disease etiologies. Using system genetics, we previously identified the human arterial wall specific GRN42 as a critical regulator of foam cell formation. In this study, we applied a GRN-driven drug repurposing method by combining transcriptional signatures resulting from the silencing of key drivers of GRN42 to drug-related gene expression profiles from the NIH LINCS Program. This analysis identified candidate compounds predicted to modulate foam cell formation. In vitro screenings of top-selected compounds confirmed the computational predictions and demonstrated the efficacy of auranofin — an FDA-approved gold salt compound for rheumatoid arthritis — in reducing foam cell formation. In vivo, auranofin reduced atherosclerosis progression and inflammation in mice and decreased inflammation and wall thickness in the rabbit atherosclerotic aorta, as measured by 18F-FDG PET/MRI. These findings suggest that a GRN-based drug repurposing approach, combined with in vitro and in vivo validation using translational molecular imaging, can uncover new uses for existing drugs, such as auranofin, for the treatment of CAD.

2026-04-01 | GSE293698 | GEO

Gene Regulatory Network-Driven Drug Repurposing Identifies Anti-Atherosclerotic Properties of Auranofin [dataset 1]

2026-04-01 | GSE293697 | GEO

Accumulation of auranofin in white adipose tissues lowers leptin levels and exerts anti-diabetic effects

Project description:Low-grade, sustained inflammation in white adipose tissue (WAT) characterizes obesity and frequently coincides with insulin resistance and type 2 diabetes (T2D). However, pharmacological targeting of WAT inflammation lacks durable therapeutic effects. Through a computational screen, we identified the FDA-approved rheumatoid arthritis drug auranofin is a putative small molecule for obesity treatment. We discovered that allometrically scaled safe auranofin doses homed to WAT and improved insulin sensitivity in obese wild-type mice. To assess the transcriptional changes underlying the beneficial effects of auranofin, we performed RNA-seq analysis on adipose and liver tissue after 4 weeks of treatment with vehicle or auranofin.

2022-10-06 | GSE202935 | GEO

Comprehensive chemical proteomics for target deconvolution of the redox active drug auranofin

Project description:Chemical proteomics encompasses novel drug target deconvolution methods in which compound modification is not required. Herein we use Thermal Proteome Profiling, Functional Identification of Target by Expression Proteomics and multiplexed redox proteomics for deconvolution of auranofin targets to aid elucidation of its mechanisms of action. Auranofin (Ridaura®) was approved for treatment of rheumatoid arthritis in 1985. Because several clinical trials are currently ongoing to repurpose auranofin for cancer therapy, comprehensive characterization of its targets and effects in cancer cells is important. Together, our chemical proteomics tools confirmed thioredoxin reductase 1 (TXNRD1) as a main auranofin target, with perturbation of oxidoreductase pathways as the top mechanism of drug action. Additional indirect targets included NFKB2 and CHORDC1. Our comprehensive data can be used as a proteomic signature resource for further analyses of the effects of auranofin. Here we also assessed the orthogonality and complementarity of different chemical proteomics methods that can furnish invaluable mechanistic information and thus the approach can facilitate drug discovery efforts in general.

2020-03-19 | PXD016776 | Pride

Rheumatoid arthritis: aortic biopsies

Project description:Analysis of biopsies of the ascending aorta from coronary artery disease patients with and without rheumatoid arthritis

2018-03-19 | GSE110008 | GEO

Auranofin targets UBA1 and enhances UBA1 activity by facilitating ubiquitin trans-thioesterificlation to E2 ubiquitin-conjugating enzymes

Project description:UBA1 is the primary E1 ubiquitin-activating enzyme, regulating stability and function of numerous proteins via initiating their ubiquitination. Decreased or insufficient ubiquitination can cause or drive aging and many deadly diseases. Therefore, a small-molecule UBA1 activity enhancer could have broad therapeutic potential. Here we report that auranofin, a drug approved for the treatment of rheumatoid arthritis is a potent UBA1 activity enhancer. Auranofin binds to the UBA1’s ubiquitin fold domain in vitro with a KD of 5.19 nM. The binding enhances UBA1 interactions with at least 20 different E2 ubiquitin-conjugating enzymes, facilitating ubiquitin charging to E2 and increasing the activities of five representative E3s in vitro. Auranofin promotes ubiquitination and degradation of misfolded ER proteins during ER-associated degradation in cells at low nanomolar concentrations. It also facilitates outer mitochondrial membrane-associated degradation. This study discovered the first small-molecule UBA1 activity enhancer, providing a much-needed tool for UBA1 research and therapeutic exploration.

2023-07-10 | PXD042558 | Pride

Auranofin improves chemotherapeutic response of breast tumor by targeting TOPBP1-nucleated protein complexes

Project description:Genome instability is most commonly caused by replication stress, which also renders cancer cells extremely vulnerable once their response to replication stress is impeded. Topoisomerase II binding protein 1 (TOPBP1), an allosteric activator of ataxia telangiectasia and Rad3 related (ATR) kinase, coordinates ATR in replication stress response and has emerged as a potential therapeutic target for tumors. Here, we identify auranofin, the FDA-approved drug for rheumatoid arthritis, as a lead compound capable of binding to the BRCT 7-8 domains and blocking TOPBP1 interaction with PHF8 and FANCJ. The liquid-liquid phase separation (LLPS) of TOPBP1 was also disrupted by auranofin. Through targeting these TOPBP1-nucleated molecular machineries, auranofin leads to an accumulation of replication defects by impairing ATR activation and attenuating RPA loading on perturbed replication forks, and it shows significant anti-breast tumor activity in combination with PARP inhibitor (PARPi). This study provides mechanistic insights into how auranofin challenges replication integrity and expands the application of this FDA-approved drug in breast tumor intervention.

| PXD066377 |

Peripheral blood gene expression profiles in metabolic syndrome, coronary artery disease and type 2 diabetes

Project description:Gene expression in peripheral blood is shown sufficient to differentiate patients with metabolic disorders from control. The signatures of metabolic syndrome, coronary artery disease and type 2 diabetes also have significant overlap. Microarrays were performed on 35 subjects in the following groups: control (n=9), rheumatoid arthritis (n=6), metabolic syndrome (n= 6), coronary artery disease (n=6) and type 2 diabetes (n=8). Intensity values for each array were normalized to a sum of 10,000.

2010-08-12 | E-GEOD-23561 | biostudies-arrayexpress